Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV–hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy
OBJECTIVES:Ribavirin (RBV) induced anemia may be influenced by host genetic factors affecting RBV transport solute carrier (SLC) or metabolism inosine triphosphatase (ITPA), as already reported. We investigated the influence of single nucleotide polymorphisms (SNPs) on SLC genes on anemia, RBV troug...
Gespeichert in:
| Veröffentlicht in: | AIDS (London) 2016-08, Vol.30 (13), p.2085-2090 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2090 |
|---|---|
| container_issue | 13 |
| container_start_page | 2085 |
| container_title | AIDS (London) |
| container_volume | 30 |
| creator | Kheloufi, Farid Bellissant, Eric Cotte, Laurent Poizot-Martin, Isabelle Quaranta, Sylvie Garraffo, Rodolphe Barrail-Tran, Aurélie Renault, Alain Fournier, Isabelle Lacarelle, Bruno Bourlière, Marc Molina, Jean-Michel Solas, Caroline |
| description | OBJECTIVES:Ribavirin (RBV) induced anemia may be influenced by host genetic factors affecting RBV transport solute carrier (SLC) or metabolism inosine triphosphatase (ITPA), as already reported. We investigated the influence of single nucleotide polymorphisms (SNPs) on SLC genes on anemia, RBV trough concentration (Ctrough) and response in HIV–hepatitis C virus coinfected patients receiving triple therapy with boceprevir or telaprevir.
METHODS:Patients from the ANRS HC26/HC27 studies were genotyped for SLC28A3 SNPs (rs10868138 and rs56350726) and SL29A1 SNPs (rs760370). Hemoglobin (Hb) decline was collected at baseline day 0 (D0), week 4 (W4) and week 8 (W8), and RBV Ctrough was measured at W4 and W8 by HPLC. A multivariate analysis including SLC SNPs, estimated glomerular filtration rate (eGFR), ITPA deficiency and RBV Ctrough was performed to determine predictive factors of anemia and response.
RESULTS:SLC genotyping was performed in 130 patients. Neither SLC28A3 nor SLC29A1 SNPs were associated with Hb decline both at W4 and W8. No association was found between SLC polymorphisms and RBV Ctrough. Independent predictive factors of Hb decline at W4 were D0 Hb, ITPA deficiency and W4 RBV Ctrough in the multivariate analysis (P |
| doi_str_mv | 10.1097/QAD.0000000000001143 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01372823v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1815694108</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3723-7e0dad58ce27138594002d737cb85c3d99c6ddf70463909313bffcedd0c46baa3</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhiMEokvhDRDyEQ4pdpys7eNqKWyllRAScLUce0IMThxsp6u98Q59nz4MT4KXlApxwJfRjL_5x56_KJ4TfEGwYK8_bN5c4L8OITV9UKxIzWjZNIw8LFa4WotSUIbPiicxfs1Qgzl_XJxVjNQCc7Eqbi9jsoNKYNAX5wcIs1MBddaloJL1I8oBUDsnNPqEondzTrUKwUJAk3fHwYept3GIyI6dm2HUEJEaYbAqV9Du6vPPHzc9TFkt2Yi26NqGOSLtMw76NPd0BWOKKAX4_ZCDTT1qvYYpQKaRDyiBU0tWtipmJvUQ1HR8WjzqlIvw7C6eF5_eXn7c7sr9-3dX282-1JRVtGSAjTIN15B_TnkjaowrwyjTLW80NULotTEdw_WaCiwooW3XaTAG63rdKkXPi1eLbq-cnELeWDhKr6zcbfbyVMMkD-IVvSaZfbmwU_DfZ4hJDjZqcC5vxc9REk6atagJ5hmtF1QHH2OA7l6bYHlyWWaX5b8u57YXdxPmdgBz3_TH1gzwBTh4lyDEb24-QJA9KJf6_2v_AtFtuaE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1815694108</pqid></control><display><type>article</type><title>Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV–hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Kheloufi, Farid ; Bellissant, Eric ; Cotte, Laurent ; Poizot-Martin, Isabelle ; Quaranta, Sylvie ; Garraffo, Rodolphe ; Barrail-Tran, Aurélie ; Renault, Alain ; Fournier, Isabelle ; Lacarelle, Bruno ; Bourlière, Marc ; Molina, Jean-Michel ; Solas, Caroline</creator><creatorcontrib>Kheloufi, Farid ; Bellissant, Eric ; Cotte, Laurent ; Poizot-Martin, Isabelle ; Quaranta, Sylvie ; Garraffo, Rodolphe ; Barrail-Tran, Aurélie ; Renault, Alain ; Fournier, Isabelle ; Lacarelle, Bruno ; Bourlière, Marc ; Molina, Jean-Michel ; Solas, Caroline ; ANRS HC27 BOCEPREVIH & HC26 TELAPREVIH Study Groups</creatorcontrib><description>OBJECTIVES:Ribavirin (RBV) induced anemia may be influenced by host genetic factors affecting RBV transport solute carrier (SLC) or metabolism inosine triphosphatase (ITPA), as already reported. We investigated the influence of single nucleotide polymorphisms (SNPs) on SLC genes on anemia, RBV trough concentration (Ctrough) and response in HIV–hepatitis C virus coinfected patients receiving triple therapy with boceprevir or telaprevir.
METHODS:Patients from the ANRS HC26/HC27 studies were genotyped for SLC28A3 SNPs (rs10868138 and rs56350726) and SL29A1 SNPs (rs760370). Hemoglobin (Hb) decline was collected at baseline day 0 (D0), week 4 (W4) and week 8 (W8), and RBV Ctrough was measured at W4 and W8 by HPLC. A multivariate analysis including SLC SNPs, estimated glomerular filtration rate (eGFR), ITPA deficiency and RBV Ctrough was performed to determine predictive factors of anemia and response.
RESULTS:SLC genotyping was performed in 130 patients. Neither SLC28A3 nor SLC29A1 SNPs were associated with Hb decline both at W4 and W8. No association was found between SLC polymorphisms and RBV Ctrough. Independent predictive factors of Hb decline at W4 were D0 Hb, ITPA deficiency and W4 RBV Ctrough in the multivariate analysis (P < 0.05). Only D0 Hb, W4 RBV Ctrough and eGFRD0–W8 were predictive of anemia at W8 (P < 0.05). Response was not influenced by SLC SNPs.
CONCLUSION:eGFR, but not SLC polymorphisms, influences anemia in HIV–hepatitis C virus coinfected patients receiving boceprevir-based or telaprevir-based therapy. RBV is still a cornerstone of hepatitis C treatment, thus renal function and RBV Ctrough should be monitored in patients receiving RBV regimen combined with first-generation direct-acting antiviral agent.</description><identifier>ISSN: 0269-9370</identifier><identifier>EISSN: 1473-5571</identifier><identifier>DOI: 10.1097/QAD.0000000000001143</identifier><identifier>PMID: 27149089</identifier><language>eng</language><publisher>England: Copyright Wolters Kluwer Health, Inc</publisher><subject>Anemia - chemically induced ; Antiviral Agents - administration & dosage ; Antiviral Agents - adverse effects ; Coinfection - complications ; Coinfection - drug therapy ; Decision Support Techniques ; Drug Therapy, Combination - adverse effects ; Drug Therapy, Combination - methods ; Female ; Genotyping Techniques ; Glomerular Filtration Rate ; Hepatitis C virus ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - drug therapy ; HIV Infections - complications ; HIV Infections - drug therapy ; Human health and pathology ; Human immunodeficiency virus ; Humans ; Lentivirus ; Life Sciences ; Male ; Membrane Transport Proteins - genetics ; Oligopeptides - administration & dosage ; Pharmacogenomic Testing ; Polymorphism, Single Nucleotide ; Proline - administration & dosage ; Proline - analogs & derivatives ; Retroviridae ; Ribavirin - administration & dosage ; Ribavirin - adverse effects</subject><ispartof>AIDS (London), 2016-08, Vol.30 (13), p.2085-2090</ispartof><rights>Copyright © 2016 Wolters Kluwer Health, Inc.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3723-7e0dad58ce27138594002d737cb85c3d99c6ddf70463909313bffcedd0c46baa3</cites><orcidid>0000-0003-0003-5556 ; 0000-0002-5676-5411</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27149089$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://univ-rennes.hal.science/hal-01372823$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Kheloufi, Farid</creatorcontrib><creatorcontrib>Bellissant, Eric</creatorcontrib><creatorcontrib>Cotte, Laurent</creatorcontrib><creatorcontrib>Poizot-Martin, Isabelle</creatorcontrib><creatorcontrib>Quaranta, Sylvie</creatorcontrib><creatorcontrib>Garraffo, Rodolphe</creatorcontrib><creatorcontrib>Barrail-Tran, Aurélie</creatorcontrib><creatorcontrib>Renault, Alain</creatorcontrib><creatorcontrib>Fournier, Isabelle</creatorcontrib><creatorcontrib>Lacarelle, Bruno</creatorcontrib><creatorcontrib>Bourlière, Marc</creatorcontrib><creatorcontrib>Molina, Jean-Michel</creatorcontrib><creatorcontrib>Solas, Caroline</creatorcontrib><creatorcontrib>ANRS HC27 BOCEPREVIH & HC26 TELAPREVIH Study Groups</creatorcontrib><title>Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV–hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy</title><title>AIDS (London)</title><addtitle>AIDS</addtitle><description>OBJECTIVES:Ribavirin (RBV) induced anemia may be influenced by host genetic factors affecting RBV transport solute carrier (SLC) or metabolism inosine triphosphatase (ITPA), as already reported. We investigated the influence of single nucleotide polymorphisms (SNPs) on SLC genes on anemia, RBV trough concentration (Ctrough) and response in HIV–hepatitis C virus coinfected patients receiving triple therapy with boceprevir or telaprevir.
METHODS:Patients from the ANRS HC26/HC27 studies were genotyped for SLC28A3 SNPs (rs10868138 and rs56350726) and SL29A1 SNPs (rs760370). Hemoglobin (Hb) decline was collected at baseline day 0 (D0), week 4 (W4) and week 8 (W8), and RBV Ctrough was measured at W4 and W8 by HPLC. A multivariate analysis including SLC SNPs, estimated glomerular filtration rate (eGFR), ITPA deficiency and RBV Ctrough was performed to determine predictive factors of anemia and response.
RESULTS:SLC genotyping was performed in 130 patients. Neither SLC28A3 nor SLC29A1 SNPs were associated with Hb decline both at W4 and W8. No association was found between SLC polymorphisms and RBV Ctrough. Independent predictive factors of Hb decline at W4 were D0 Hb, ITPA deficiency and W4 RBV Ctrough in the multivariate analysis (P < 0.05). Only D0 Hb, W4 RBV Ctrough and eGFRD0–W8 were predictive of anemia at W8 (P < 0.05). Response was not influenced by SLC SNPs.
CONCLUSION:eGFR, but not SLC polymorphisms, influences anemia in HIV–hepatitis C virus coinfected patients receiving boceprevir-based or telaprevir-based therapy. RBV is still a cornerstone of hepatitis C treatment, thus renal function and RBV Ctrough should be monitored in patients receiving RBV regimen combined with first-generation direct-acting antiviral agent.</description><subject>Anemia - chemically induced</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - adverse effects</subject><subject>Coinfection - complications</subject><subject>Coinfection - drug therapy</subject><subject>Decision Support Techniques</subject><subject>Drug Therapy, Combination - adverse effects</subject><subject>Drug Therapy, Combination - methods</subject><subject>Female</subject><subject>Genotyping Techniques</subject><subject>Glomerular Filtration Rate</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>Human health and pathology</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Lentivirus</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Membrane Transport Proteins - genetics</subject><subject>Oligopeptides - administration & dosage</subject><subject>Pharmacogenomic Testing</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Proline - administration & dosage</subject><subject>Proline - analogs & derivatives</subject><subject>Retroviridae</subject><subject>Ribavirin - administration & dosage</subject><subject>Ribavirin - adverse effects</subject><issn>0269-9370</issn><issn>1473-5571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu1DAQhiMEokvhDRDyEQ4pdpys7eNqKWyllRAScLUce0IMThxsp6u98Q59nz4MT4KXlApxwJfRjL_5x56_KJ4TfEGwYK8_bN5c4L8OITV9UKxIzWjZNIw8LFa4WotSUIbPiicxfs1Qgzl_XJxVjNQCc7Eqbi9jsoNKYNAX5wcIs1MBddaloJL1I8oBUDsnNPqEondzTrUKwUJAk3fHwYept3GIyI6dm2HUEJEaYbAqV9Du6vPPHzc9TFkt2Yi26NqGOSLtMw76NPd0BWOKKAX4_ZCDTT1qvYYpQKaRDyiBU0tWtipmJvUQ1HR8WjzqlIvw7C6eF5_eXn7c7sr9-3dX282-1JRVtGSAjTIN15B_TnkjaowrwyjTLW80NULotTEdw_WaCiwooW3XaTAG63rdKkXPi1eLbq-cnELeWDhKr6zcbfbyVMMkD-IVvSaZfbmwU_DfZ4hJDjZqcC5vxc9REk6atagJ5hmtF1QHH2OA7l6bYHlyWWaX5b8u57YXdxPmdgBz3_TH1gzwBTh4lyDEb24-QJA9KJf6_2v_AtFtuaE</recordid><startdate>20160824</startdate><enddate>20160824</enddate><creator>Kheloufi, Farid</creator><creator>Bellissant, Eric</creator><creator>Cotte, Laurent</creator><creator>Poizot-Martin, Isabelle</creator><creator>Quaranta, Sylvie</creator><creator>Garraffo, Rodolphe</creator><creator>Barrail-Tran, Aurélie</creator><creator>Renault, Alain</creator><creator>Fournier, Isabelle</creator><creator>Lacarelle, Bruno</creator><creator>Bourlière, Marc</creator><creator>Molina, Jean-Michel</creator><creator>Solas, Caroline</creator><general>Copyright Wolters Kluwer Health, Inc</general><general>Wolters Kluwer</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7T5</scope><scope>7U2</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-0003-5556</orcidid><orcidid>https://orcid.org/0000-0002-5676-5411</orcidid></search><sort><creationdate>20160824</creationdate><title>Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV–hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy</title><author>Kheloufi, Farid ; Bellissant, Eric ; Cotte, Laurent ; Poizot-Martin, Isabelle ; Quaranta, Sylvie ; Garraffo, Rodolphe ; Barrail-Tran, Aurélie ; Renault, Alain ; Fournier, Isabelle ; Lacarelle, Bruno ; Bourlière, Marc ; Molina, Jean-Michel ; Solas, Caroline</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3723-7e0dad58ce27138594002d737cb85c3d99c6ddf70463909313bffcedd0c46baa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Anemia - chemically induced</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - adverse effects</topic><topic>Coinfection - complications</topic><topic>Coinfection - drug therapy</topic><topic>Decision Support Techniques</topic><topic>Drug Therapy, Combination - adverse effects</topic><topic>Drug Therapy, Combination - methods</topic><topic>Female</topic><topic>Genotyping Techniques</topic><topic>Glomerular Filtration Rate</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>Human health and pathology</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Lentivirus</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Membrane Transport Proteins - genetics</topic><topic>Oligopeptides - administration & dosage</topic><topic>Pharmacogenomic Testing</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Proline - administration & dosage</topic><topic>Proline - analogs & derivatives</topic><topic>Retroviridae</topic><topic>Ribavirin - administration & dosage</topic><topic>Ribavirin - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kheloufi, Farid</creatorcontrib><creatorcontrib>Bellissant, Eric</creatorcontrib><creatorcontrib>Cotte, Laurent</creatorcontrib><creatorcontrib>Poizot-Martin, Isabelle</creatorcontrib><creatorcontrib>Quaranta, Sylvie</creatorcontrib><creatorcontrib>Garraffo, Rodolphe</creatorcontrib><creatorcontrib>Barrail-Tran, Aurélie</creatorcontrib><creatorcontrib>Renault, Alain</creatorcontrib><creatorcontrib>Fournier, Isabelle</creatorcontrib><creatorcontrib>Lacarelle, Bruno</creatorcontrib><creatorcontrib>Bourlière, Marc</creatorcontrib><creatorcontrib>Molina, Jean-Michel</creatorcontrib><creatorcontrib>Solas, Caroline</creatorcontrib><creatorcontrib>ANRS HC27 BOCEPREVIH & HC26 TELAPREVIH Study Groups</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Safety Science and Risk</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>AIDS (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kheloufi, Farid</au><au>Bellissant, Eric</au><au>Cotte, Laurent</au><au>Poizot-Martin, Isabelle</au><au>Quaranta, Sylvie</au><au>Garraffo, Rodolphe</au><au>Barrail-Tran, Aurélie</au><au>Renault, Alain</au><au>Fournier, Isabelle</au><au>Lacarelle, Bruno</au><au>Bourlière, Marc</au><au>Molina, Jean-Michel</au><au>Solas, Caroline</au><aucorp>ANRS HC27 BOCEPREVIH & HC26 TELAPREVIH Study Groups</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV–hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy</atitle><jtitle>AIDS (London)</jtitle><addtitle>AIDS</addtitle><date>2016-08-24</date><risdate>2016</risdate><volume>30</volume><issue>13</issue><spage>2085</spage><epage>2090</epage><pages>2085-2090</pages><issn>0269-9370</issn><eissn>1473-5571</eissn><abstract>OBJECTIVES:Ribavirin (RBV) induced anemia may be influenced by host genetic factors affecting RBV transport solute carrier (SLC) or metabolism inosine triphosphatase (ITPA), as already reported. We investigated the influence of single nucleotide polymorphisms (SNPs) on SLC genes on anemia, RBV trough concentration (Ctrough) and response in HIV–hepatitis C virus coinfected patients receiving triple therapy with boceprevir or telaprevir.
METHODS:Patients from the ANRS HC26/HC27 studies were genotyped for SLC28A3 SNPs (rs10868138 and rs56350726) and SL29A1 SNPs (rs760370). Hemoglobin (Hb) decline was collected at baseline day 0 (D0), week 4 (W4) and week 8 (W8), and RBV Ctrough was measured at W4 and W8 by HPLC. A multivariate analysis including SLC SNPs, estimated glomerular filtration rate (eGFR), ITPA deficiency and RBV Ctrough was performed to determine predictive factors of anemia and response.
RESULTS:SLC genotyping was performed in 130 patients. Neither SLC28A3 nor SLC29A1 SNPs were associated with Hb decline both at W4 and W8. No association was found between SLC polymorphisms and RBV Ctrough. Independent predictive factors of Hb decline at W4 were D0 Hb, ITPA deficiency and W4 RBV Ctrough in the multivariate analysis (P < 0.05). Only D0 Hb, W4 RBV Ctrough and eGFRD0–W8 were predictive of anemia at W8 (P < 0.05). Response was not influenced by SLC SNPs.
CONCLUSION:eGFR, but not SLC polymorphisms, influences anemia in HIV–hepatitis C virus coinfected patients receiving boceprevir-based or telaprevir-based therapy. RBV is still a cornerstone of hepatitis C treatment, thus renal function and RBV Ctrough should be monitored in patients receiving RBV regimen combined with first-generation direct-acting antiviral agent.</abstract><cop>England</cop><pub>Copyright Wolters Kluwer Health, Inc</pub><pmid>27149089</pmid><doi>10.1097/QAD.0000000000001143</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-0003-5556</orcidid><orcidid>https://orcid.org/0000-0002-5676-5411</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-9370 |
| ispartof | AIDS (London), 2016-08, Vol.30 (13), p.2085-2090 |
| issn | 0269-9370 1473-5571 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01372823v1 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
| subjects | Anemia - chemically induced Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Coinfection - complications Coinfection - drug therapy Decision Support Techniques Drug Therapy, Combination - adverse effects Drug Therapy, Combination - methods Female Genotyping Techniques Glomerular Filtration Rate Hepatitis C virus Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy HIV Infections - complications HIV Infections - drug therapy Human health and pathology Human immunodeficiency virus Humans Lentivirus Life Sciences Male Membrane Transport Proteins - genetics Oligopeptides - administration & dosage Pharmacogenomic Testing Polymorphism, Single Nucleotide Proline - administration & dosage Proline - analogs & derivatives Retroviridae Ribavirin - administration & dosage Ribavirin - adverse effects |
| title | Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV–hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T02%3A48%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Estimated%20glomerular%20filtration%20rate%20but%20not%20solute%20carrier%20polymorphisms%20influences%20anemia%20in%20HIV%E2%80%93hepatitis%20C%20virus%20coinfected%20patients%20treated%20with%20boceprevir%20or%20telaprevir-based%20therapy&rft.jtitle=AIDS%20(London)&rft.au=Kheloufi,%20Farid&rft.aucorp=ANRS%20HC27%20BOCEPREVIH%20&%20HC26%20TELAPREVIH%20Study%20Groups&rft.date=2016-08-24&rft.volume=30&rft.issue=13&rft.spage=2085&rft.epage=2090&rft.pages=2085-2090&rft.issn=0269-9370&rft.eissn=1473-5571&rft_id=info:doi/10.1097/QAD.0000000000001143&rft_dat=%3Cproquest_hal_p%3E1815694108%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1815694108&rft_id=info:pmid/27149089&rfr_iscdi=true |